Doctors in 50 states, pharmacy, 3% processing, LegitScript in about two weeks, from the team behind glp-1.com and payments for 90 peptide brands. Done with you, where you drive and keep 100%, or done for you, where we run everything and hold equity until your exit. Not a platform, not an agency; the launch machine on top of both.
I don't expect you to watch this whole video before applying, but it would be good to read this whole page before doing so.
Are you:
Not for you if you don't have an audience, a list, or a customer base yet. This is licensed patient care under a brand you own.
Not ready to launch? Be an affiliate instead: promote one of our telehealth brands, and we'll support you in promoting it.
You've got three options. Two of them are bad.
Send your people to somebody else's brand. They keep the patients, the rebills, and the business. You get a cut, and the day you stop posting, it stops.
An attorney, a doctor network, a pharmacy deal, your own LegitScript, a site, ads, and the compliance to not get fined. Past $50,000 and most of a year. If you get it right.
You own the brand, and the machine is already built: doctors, pharmacy, payments, compliance. A partnership done for you, or a sprint done with you. Live and taking patients inside a week.
One is done with you. One is done for you. Both deals in full, before you ever get on a call with us.
One-time, no equity, no monthly. Same build either way; the term is how long the team stays in it with you. You drive, and you keep 100% of everything.
The Sprint runs in cohorts, so everyone starts together. We're holding these prices through this cohort because we'd rather move everyone who's ready now than drip them in. The price goes up for the next cohort.
When you outgrow driving it yourself, the Partnership is where you land.
We build and run the whole company for you. You pay us for the work, we hold 20% beside you, and the platform and catalog pass through with no markup.
Ten founding seats.
Hard costs like LegitScript certification fees (~$4,000) and your ad budget pass through at cost, and on the Partnership we fund the first $5,000 of ad budget ourselves. The normal running costs of any telehealth business (pharmacy per order, clinician fees, processing) are paid as you go, exactly as before.
The same decision, mapped side by side.
| A platform, alone | A platform + an agency | The Sprintdone with you | The Partnershipdone for you | |
|---|---|---|---|---|
| Who builds your brand | You, alone | The agency, at their pace | You, with a site we build and our map, scripts, and intros | Our team, for you |
| Who runs it after launch | You | You; they run the ads | You | Our operating team, with you |
| Support when it's hard | The keys and a good-luck email | Whatever the retainer covers | Launch week, plus weekly mastermind calls your whole term | Daily calls until your first ten patients |
| How they get paid | The day you sign up | Every month, win or lose | Once, flat | For the work now, and 20% when you sell |
| Who wins when you sell | Not their problem | Not their problem | You. You keep 100% | Both of us: books kept diligence-ready, and our 20% only pays if the sale happens |
| The cost shape | Platform fee, plus every mistake | Platform fee, plus the retainer | $9,800 / 3 months or $14,800 / 6, one time | $30,000 + $5,000/mo from Day 30 + 20% equity |
Two ways in: a launch partnership done for you with 20% equity, or a flat-fee launch sprint done with you. You'll get the exact numbers on your call, and nothing on it will surprise you.
Each of these is a wall that stops people from ever starting. We take all of them down in the build. Everything here ships in both lanes unless it says Partnership.
Wyoming LLC, business bank account approved in about a day, Stripe live before LegitScript, legally.
Application prepped and driven to certification before Stripe ever asks.
Name, domain strategy, and a conversion-built site, live and compliant.
White-label telehealth platform at our negotiated rate, catalog at cost, zero markup.
Tracking, email, text, automations, live dashboards, and a Slack channel with our team inside.
Your intake funnel launched to the audience you already own, patients before the site is even polished.
The messaging that makes people bang down your door, plus name-and-likeness exit terms in every influencer contract.
Refill automations and win-back flows from day one. Recurring revenue is the asset; this defends it.
Finance, patient-side care coordination, cart recovery, creative, from Day 30.
Quarterly audits keeping your books the way an acquirer reads them, from month one.
Both lanes launch the same way. Three tracks start at once: your money rails, the LegitScript clock, and the patient path. We front-load the patients through your warm network, so revenue can start in week one, before the website or LegitScript even matter.
The long pole is LegitScript, so the brand and domain get locked on Day 0 to start that clock. Everything else races ahead of it.
The launch timeline showed the sequence. This is the demand play inside it: the workshop engine we run to bring your first patients in, for any brand with an audience. Start to finish. On the Partnership, our team runs every step for you. On the Sprint, you drive the steps with our materials, our weekly calls, and the team on Slack.
You get: the format, the deck, the registration page, and a clinician from our network on the call when you want one.
You get: the promo scripts, the content frameworks, and the reminder sequence that gets people to show up.
You get: the workshop-to-intake flow, wired before the call starts.
You get: the referral playbook your patients follow.
You get: the replay setup and the follow-up series, written for you.
You get: the agency ad accounts and the creative, pointed at what the workshop proved.
That's one launch mechanism. We duplicate it, brand after brand, workshop after workshop.
Every starter platform carries the same short menu: semaglutide, tirzepatide, testosterone, and the same pills everyone has seen a hundred ads for. Identical brands, identical products, margin bleeding out on price. Three things separate yours.
We partner with doctor networks that prescribe what the big platforms won't touch: BPC-157, GHK-Cu, NAD+, sermorelin, TB-500, CJC-1295, and a formulary that runs dozens deep. Most are not FDA-approved, and nobody pretends otherwise. Doctors prescribe them on their own clinical judgment, where their state boards allow it, and because many of these compounds can't be patented, no pharma giant has a billion-dollar reason to clear the field.
The drugs are commodities. The difference is the blood work: full panels, read by a licensed team, turned into a plan for each patient. People stay because somebody is tracking what's happening in their body. A research brand can't even suggest a blood test without implying human use.
A licensed brand gets to bolt on the next generation of medicine as it lands: advanced lab assessments, less invasive mitochondrial testing, AI-assisted diagnostics. Every new tool raises what your brand is worth. Research brands are locked out of that entire world.
Put in your audience and your price. Your exit value shows up: what a buyer pays you the day you sell, not a monthly check. Pick a scenario, or build your own.
Same 1,000 people, valued two ways. As a research brand they order about $250 every other month, roughly $1.5M a year at the high margins these brands run, and they trade around 3x profit. Licensed, those same people are on a $350 monthly protocol with cross-sells, roughly $4.2M a year, and telehealth trades on revenue. The multiple is a notch better. The monetization is a lot better.
Same 1,000 people, and the licensed brand is worth roughly four times more.
Most of the gap is monetization, not the multiple. The licensed brand earns about 2.8x more from the same people, because a $350 monthly protocol with cross-sells beats $250 every other month. The multiple only adds a little on top: roughly 3x revenue for licensed telehealth against about 2.3x for a research brand. A research brand is a good business. This is a bigger one, built on the customers you already have.
Strategics, private equity, and operators all shop licensed telehealth. A research brand sells into a thin, nervous pool, and a small pool prices low.
A monthly protocol with a doctor behind it retains far better than sporadic vial orders. Buyers pay up for revenue that stays.
Same patient, more to sell: lab panels, supplements, ED, hair loss, HRT. What a patient is worth expands instead of flatlining.
Retention and expansion are what a multiple prices. Which is why 3x is the conservative read here, not the optimistic one.
Illustrative only. You choose every input, so the output is your assumption, not a projection, valuation, guarantee, or promise of earnings. Small brands sell on owner earnings; a revenue multiple applies once you scale past roughly $1 million a year in revenue. Research-side figures assume $250 average order value every other month, the 70 to 78% profit margins these brands run, and about 3x profit. Telehealth figures are gross of pharmacy, clinician, processing, and ad costs. What a company sells for depends on the market, its margins, and its execution.
Like your numbers? The call is where the team runs them against your audience.
Payments and distribution on one side. Telehealth operations on the other. An operating crew underneath.
Behind them, the operating crew. Finance, patient-side care coordination, cart recovery, creative, and vendors, from Day 30.
Our biggest payday is your exit. We charge for the work, and we hold 20% that is worth nothing unless your brand is worth buying.
sermorelin.com alone already draws around 20,000 organic visitors a month.
Not mockups. Live category properties, pulling organic traffic right now. Tap one.

You keep the equity in your own brand, and you can exit it on your own. Mark and I hold 20% of every Partnership brand we build, plus the domain portfolio and the distribution, and we take all of it to one big exit together. We get paid for the work along the way, but the prize we're playing for is the same one you're playing for.
It pays at your exit, not before.
Everyone else selling a platform is saying buy from us, and good luck. Here's the keys, good luck driving this rocket ship. Oh, I'm not an astronaut. I'm going to crash. That's what most of these brands end up doing.Mark, operations partner, on the other platforms
You're not buying a course or a login. You're buying a system, built and run by a team that has launched this before. You never touch the medicine, and you never give medical advice. This is the Partnership lane, done for you. The Sprint is done with you: you drive, we hand you the rails.
An audience, list, or customer base you already own.
Approve the direction and make the decisions with our team.
The investment and your ad budget. The rest is ours to run.
You don't have to be the face. Front it yourself if you want to, put a creator on it, or stay behind the brand entirely. The one thing we can't build is your distribution. Everything else is on us.
Patients rebill every month whether you worked that day or not. Your revenue arrives on a schedule instead of starting from zero every morning. Your business has a clean profit and loss, the kind a buyer reads and likes.
And you are not refreshing a processor dashboard praying it still works, because nobody freezes a doctor writing a valid prescription. You own something now. Not a hustle that can disappear. An asset you could sell. And every quarter, your books get reviewed the way an acquirer will one day read them, because the partner who owns 20% of your exit has every reason to keep you sellable.
And the peptide wave hasn't broken yet. GLP-1s are already racing toward 50% adoption. Peptides are still under 5%, the exact spot GLP-1s were in right before they went mainstream. Every fitness influencer is about to be talking about peptides, and Washington is deciding on peptide compounding right now, with the card networks, the banks, and the VCs all waiting on the answer before the money floods in. Get in front of the wave now, and you are the brand everyone else chases later.
They come with the Partnership seat.
Live, processing, and your first patient campaign in-market within 30 days of kickoff, or the monthly is waived until it's done. Late weeks are on us. (Your side: brand decision by Day 2, documents signed on schedule, training attended.)
Daily calls with our team until your first ten patients are in. However long it takes.
Our 20% is worth zero if your brand goes nowhere. The fees pay for the build; the equity only pays if you win. Their guarantee is a refund policy. Ours is the deal itself.
All three come with the seat. The application takes a few minutes.
Ten founding seats on the Partnership, and the Sprint closes when the next cohort starts. Apply below. If it's a fit, you get on a call with the team, we look at your audience, map your launch, and run your numbers, and you know by the end of it, either way.
See If You QualifyP.S. Every platform in telehealth is done making money the day you sign up. On the Partnership, we're not done until the day you sell your company. Read that twice, then hit the button.